{
  "docId": "019dd923-622c-750b-8b96-fcb164354e3e",
  "docSlug": "86ed72671dc5",
  "documentTitle": "PeptiDream, Inc. (4587 JP)",
  "authorId": "51_Muddy_Waters",
  "authorName": "Carson C. Block",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2019-11-07 00:00:00",
  "orientation": "portrait",
  "aspectRatio": 0.77272725,
  "pageNumber": 11,
  "pageCount": 22,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "villain_critique",
  "function": "name_villain",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a comparative analogy to Sosei to frame PeptiDream's strategy as a failure-prone path.",
  "elementsJson": [
    "paragraph"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b96-fcb164354e3e/11",
  "deckHref": "/decks/019dd923-622c-750b-8b96-fcb164354e3e",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b96-fcb164354e3e.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b96-fcb164354e3e#slide-11",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "In our experience, when companies' disclosures become more opaque, it's usually to obscure bad news from investors.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-14dd-72ca-b97a-f3c34d4d9a63",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.76,
        "x": 0.12,
        "y": 0.39
      },
      "kind": "paragraph",
      "text": "We believe that an in-house pipeline focus for the Company will continue to show the limitations of PeptiDream's development platform, as it will likely report disappointing lack of progress quarter after quarter - just as Sosei did.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "493b6c0d-6df9-40d0-8dfa-50be61ea248c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.76,
        "x": 0.12,
        "y": 0.22
      },
      "kind": "paragraph",
      "text": "PeptiDream has yet to successfully out-license any of its in-house projects. In an April 2014 press release, the company provided an update on its proprietary development program for influenza and stated that it expected to file an application to begin human trials in 2015.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8e40f53e-24ed-42b2-a717-99116786c5b4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.76,
        "x": 0.12,
        "y": 0.53
      },
      "kind": "paragraph",
      "text": "PeptiDream attempts to obscure the details of its track record and prospects. The company presents revenue on its portfolio of programs lumped together as generic \"programs,\" with no detail on how the programs break down.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a9640503-8b78-400e-8885-ff269fd3f60d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.76,
        "x": 0.12,
        "y": 0.14
      },
      "kind": "paragraph",
      "text": "PeptiDream's shift to an in-house drug development strategy is reminiscent of Sosei, which similarly pivoted to developing its own drugs before its stock price collapsed.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c2aecdae-ebb8-438f-b2bb-267c43a3a4d1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.76,
        "x": 0.12,
        "y": 0.65
      },
      "kind": "paragraph",
      "text": "In our experience, when companies' disclosures become more opaque, it's usually to obscure bad news from investors.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e8c3d9cc-7ac6-4646-a6d3-e80ed5270491",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.45,
        "x": 0.12,
        "y": 0.1
      },
      "kind": "title",
      "text": "In-House Development is Unlikely to Succeed",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6189a3c9-27b4-4eb9-a180-8184c08afc7c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.6,
        "x": 0.12,
        "y": 0.49
      },
      "kind": "title",
      "text": "PeptiDream Obfuscates its Failures through Increasing Opacity",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "68512364-51a0-43ec-86d0-c1dc2b75b708",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "argument-from-analogy",
      "slug": null,
      "matchId": "61ebda54-d2e5-4514-901f-484f7e947203",
      "evidence": "Comparing PeptiDream's strategy to Sosei's failed pivot.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}